证券记录 · 已归档季度
RIGL
Rigel Pharmaceuticals, Inc. · Healthcare · Biotechnology
18被追踪持有人
+3Δ持有人
6.87M持有股份
$194.53M报告持仓市值
+3新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +20.0% ·
股份流向 +26.6% ·
净新建仓位 +16.7%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 535.68K | $25.79M | +1 | n/a |
| Q2 2026 | 72 | -2 | 9.47M | $370.29M | +3 | −5 |
| Q1 2026 | 77 | -10 | 11.13M | $301.00M | n/a | −10 |
| Q4 2025 | 86 | +1 | 11.49M | $491.92M | +1 | n/a |
| Q3 2025 | 18 | +3 | 6.87M | $194.53M | +3 | n/a |
| Q2 2025 | 12 | +2 | 4.47M | $83.70M | +2 | n/a |
| Q1 2025 | 7 | -1 | 1.55M | $27.81M | +2 | −3 |
| Q4 2024 | 8 | +4 | 1.41M | $23.66M | +5 | −1 |
| Q3 2024 | 3 | -2 | 554.02K | $8.97M | n/a | −2 |
| Q2 2024 | 5 | n/a | 605.71K | $4.98M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 1.72M | +6.1% | $48.87M | 0.0% | ▲ Add | 2 | SEC ↗ ×10 |
| 2 | The Vanguard Group ✦ (被动) | 1.04M | -0.9% | $29.55M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 3 | Goldman Sachs Group ✦ | 737.03K | n/a | $20.88M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 601.33K | +63.0% | $17.04M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (被动) | 554.32K | -7.6% | $15.70M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 474.21K | +100.6% | $13.43M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (被动) | 423.72K | +1.9% | $12.01M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | D. E. Shaw & Co. ✦ | 306.49K | 新增 | $8.68M | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 220.30K | +474.6% | $6.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 186.33K | +747.6% | $5.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Morgan Stanley ✦ | 146.27K | n/a | $4.14M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | Millennium Management ✦ | 105.30K | +236.9% | $2.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 86.46K | 新增 | $2.45M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | JPMorgan Chase ✦ | 69.92K | n/a | $1.98M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 15 | Wellington Management ✦ | 61.77K | -3.2% | $1.75M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 16 | Fidelity (FMR) ✦ | 59.09K | +1641.4% | $1.67M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 17 | AQR Capital Management ✦ | 56.60K | +463.9% | $1.60M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 18 | T. Rowe Price ✦ | 9.29K | 新增 | $264,000 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| D. E. Shaw & Co. | $8.68M | 0.0% |
| Citadel Advisors | $2.45M | 0.0% |
| T. Rowe Price | $264,000 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 146 持有人, 15.81M 股份, $391.97M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
Aug 14
SC 13G/A: ARMISTICE CAPITAL, LLC
Aug 13
SC 13G/A: Soleus Capital Master Fund, L.P.
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据